News | November 14, 2022
Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
Subscribe To Our Newsletter & Stay Updated
